ABAmber L. Beitelshees

Amber L. Beitelshees

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amber L. Beitelshees has a total of 308 co-authors. Here are the top co-authors by number of shared publications:

  • Craig R. Lee

    Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

    9 shared publications
  • Dominick Joseph Angiolillo

    Division of Cardiology, Department of Medicine, College of Medicine‐Jacksonville University of Florida Jacksonville Florida USA

    8 shared publications
  • Larisa H. Cavallari

    Department of Pharmacotherapy and Translational Research University of Florida Gainesville Florida USA

    8 shared publications
  • Julie A. Johnson

    Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine College of Pharmacy, University of Florida Gainesville FL USA

    6 shared publications
  • Julio D. Duarte

    Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, United States

    6 shared publications
  • Francesco Franchi

    Division of Cardiology, Department of Medicine College of Medicine‐Jacksonville, University of Florida Jacksonville FL USA

    5 shared publications

Latest Publications

  • Open Access

    CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches

    by Rachael M. Stone, Glenda Hoffecker, April Schultz, Brittney H. Davis, Salma A. Bargal, Amber L. Beitelshees, Nihal El Rouby, Madeline Norris, Kevin J. Rodriguez, Nita Limdi, et al.

    Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no‐function alleles. While CYP2C19 ‐guided DAPT is well‐established for some cardiovascular indications, its use in neurovascular settings has remained limited until recently. This study characterized current implementation strategies for CYP2C19 ‐guided DAPT for neurovascular indications across institutions in the Pharmacogenomics Global Research Network Implementation Working Group. A REDCap survey was distributed to 54 institutions targeting those currently utilizing or planning to implement CYP2C19 testing to guide clopidogrel use for neurovascular indications. The survey collected data on implementation status, workflows, testing logistics, clinical decision support (CDS), and guideline concordance. Fifteen institutions met inclusion criteria; 80% were in the United States and 87% were academic centers. CYP2C19 testing was used for neurovascular indications at 12 sites, most commonly for AIS, intracranial aneurysm repair, and intracranial stenting. Implementation was often built on infrastructure previously established for cardiovascular indications. Most sites used multigene panels, offered testing in both inpatient and outpatient settings, and returned results within 7 days. Eighty percent of sites provided CDS to support application of results. All sites recommended an alternative P2Y12 inhibitor (e.g., ticagrelor) for poor metabolizers, and most did for intermediate metabolizers. CYP2C19 ‐guided antiplatelet therapy for neurovascular indications is expanding, with many implementations leveraging preexisting infrastructure from cardiovascular settings. Broader adoption and outcome‐focused research are needed to optimize the clinical utility of genotype‐guided DAPT in neurovascular care.


  • Open Access

    Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI

    by Caroline W. Grant, Brenden S. Ingraham, Ryan J. Lennon, Anvi Raina, Shulan Tian, Gurukripa Kowlgi, Larisa H. Cavallari, Craig R. Lee, Amber Beitelshees, Dominick J. Angiolillo, et al.

    Ischemic events after contemporary percutaneous coronary intervention (PCI) are uncommon but carry high morbidity/mortality. Identifying patients at highest risk is critical to guide dual antiplatelet therapy (DAPT) intensity while minimizing bleeding. Current machine learning (ML) model‐developed risk scores do not incorporate pharmacogenetic data. To develop and externally validate ML models that integrate clinical, demographic, and CYP2C19 genetic information to predict 1‐year ischemic outcomes post‐PCI to refine clinical decision making. We analyzed 8317 patients from TAILOR‐PCI trial ( n = 4572) and the Precision PCI registry ( n = 3745). The outcome was a composite of cardiovascular death, myocardial infarction, stroke, and stent thrombosis at 1 year. Boruta feature selection identified 11 predictors. Multiple ML algorithms were trained in TAILOR‐PCI and validated in Precision PCI using cross‐validation and synthetic minority oversampling (SMOTE). Model performance was assessed by area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. The best external performance was achieved with a support vector machine (SVM, polynomial kernel) (AUC 0.667; sensitivity 0.871; specificity 0.282), while XGBoost provided a more balanced profile (AUC 0.619; sensitivity 0.442; specificity 0.688). Variable importance for the SVM polynomial model demonstrated that all 11 included Boruta feature selected predictors had relatively high importance (> 75). ML models trained on large clinical trial and real‐world registry datasets can help identify the small subset of patients at high ischemic risk after PCI. This distinction is of relevance because ischemic events are rare, and most patients may safely de‐escalate DAPT to reduce bleeding risk while maintaining ischemic protection through a multimodal approach to risk stratification. Trial Registration: TAILOR‐PCI URL: https://clinicaltrials.gov/ct2/show/NCT01742117

  • Open Access

    2025 Acute Coronary Syndrome Guideline: Missing the Boat on CYP2C19 Genotyping

    by Larisa H. Cavallari, Craig R. Lee, Amber L. Beitelshees, Jasmine A. Luzum, George A. Stouffer, Jurriën M. Ten Berg, Wout W. A. van Den Broek, Naveen L. Pereira, Dirk Sibbing, Dominick J. Angiolillo

    The 2025 American College of Cardiology/American Heart Association/American College of Emergency Physicians/National Association of Emergency Medical Services Physicians/Society for Cardiovascular Angiography & Interventions acute coronary syndrome guideline focuses on strategies to reduce bleeding risk with antiplatelet therapy yet lacks any recommendation related to CYP2C19 genotyping. The impact of CYP2C19 loss‐of‐function alleles on the effectiveness of clopidogrel is well documented, and although prasugrel and ticagrelor more effectively reduce the risk for atherothrombotic events compared with clopidogrel in patients with a CYP2C19 loss‐of‐function allele, clopidogrel reduces bleeding risk without an increase in atherothrombotic events compared with prasugrel or ticagrelor in those without a loss‐of‐function allele. Accordingly, an American Heart Association Scientific Statement supports CYP2C19 genetic testing before oral P2Y 12 inhibitors are prescribed. This commentary summarizes the evidence in support of CYP2C19 ‐guided P2Y 12 inhibitor selection in the context of other 2025 acute coronary syndrome guideline recommendations and urges future guidelines to incorporate recommendations for CYP2C19 genotyping, especially for those at high bleeding risk.


  • Open Access

    Genetics of Response to Canagliflozin ( GRC ) Study: Rationale, Design, and Pharmacodynamic Responses

    by May E. Montasser, Salma A. Bargal, Elizabeth A. Streeten, Hilary B. Whitlatch, Zhinous Shahidzadeh Yazdi, Jordin Sirody, Rosanna Kiplagat, Merna Beshara, Jeffrey R. O’COnnell, Simeon I. Taylor, et al.

    Sodium glucose cotransporter‐2 (SGLT2) inhibitors are a class of antidiabetics with benefits including HbA1c‐lowering, weight loss, cardiovascular and renal protection in addition to adverse effects including genitourinary tract infections, ketoacidosis, and bone loss. Here, we describe the rationale and design of the Genetics of Response to Canagliflozin (GRC) study and report on the pharmacodynamic findings. This study, for which enrollment has been completed, was conducted in healthy Amish individuals with a goal of identifying genetic predictors of variability in safety and efficacy of the SGLT2 inhibitor canagliflozin. Participants took canagliflozin 300 mg/day for 5 days, completed a 24‐h urine collection, and had blood drawn at baseline, Day 3, and Day 6. The primary endpoint is glucosuria and the secondary endpoints assess additional biomarkers for safety and efficacy related to bone, cardiovascular disease, and ketosis. 402 participants completed the study. We identified significant variability in the degree of canagliflozin‐induced glucosuria with a heritability of 34% ( p = 8.69e−03). Canagliflozin induced significant increases in serum phosphorous (Day 3: +5.0%, p = 5.83e−21) and fibroblast growth factor‐23 (Day 3: +20.2%, p = 1.58e−18), decrease in 1,25‐dihydroxyvitamin D (Day 3: −25.0%, p = 5.71e−54), and increase in parathyroid hormone: (Day 3: +20.8%, p = 1.98e−33). Canagliflozin also significantly decreased serum uric acid (Day 6: −33.2%, p = 1.01e−65) and increased beta‐hydroxybutyrate (Day 3: +71.9%, p = 8.11e−28). The most significant baseline characteristic associated with glucosuria was eGFR ( p = 8.10e−10). This study will provide the opportunity to identify genetic and other 'omic predictors of safety and efficacy biomarkers for SGLT2 inhibitor response that could help guide diabetes treatment in the future.


  • Open Access

    Attitudes toward returning pathogenic KCNQ1 variant and uptake of cascade screening in the Amish

    by Elizabeth A. Streeten, Yue Guan, Kathleen A. Ryan, Melanie Daue, Toni I. Pollin, Kristen C.R. Wood, Kristin A. Maloney, Alan R. Shuldiner, Braxton D. Mitchell, Devyani Chowdhury, et al.

  • Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel‐Treated Participants

    by Luis Ortega‐Paz, Cameron D. Thomas, Claudio Laudani, Salvatore Giordano, Francesco Franchi, Kayla R. Tunehag, Fabiana Rollini, Selina Durukan, Joseph S. Rossi, Maryam Farahmandsadr, et al.

    Black individuals undergoing percutaneous coronary intervention (PCI) experience higher rates of major adverse cardiovascular events (MACE) than non‐Black individuals. This study assessed the racial differences in platelet reactivity and clinical outcomes among clopidogrel‐treated participants. Two cohorts were analyzed. The pharmacodynamic (PD) cohort involved patients with atherosclerotic cardiovascular disease on maintenance clopidogrel therapy undergoing platelet function testing. The primary outcome was high platelet reactivity (HPR, i.e., P2Y 12 reaction unit [PRU] > 208). The PCI cohort included participants undergoing PCI on clopidogrel‐based dual antiplatelet therapy. The primary outcome was 1‐year MACE, defined as the composite of cardiovascular death, myocardial infarction (MI), ischemic stroke, or stent thrombosis. Data on clinically significant bleeding and CYP2C19 genotyping alleles were collected. The PD and PCI cohorts included 728 (32.1% Black) and 2,770 (20.5% Black) participants, respectively. Black participants had higher PRU levels (184 [IQR 128–234] vs. 144 [IQR 88–195]; P < 0.001) and higher prevalence of HPR (39.3% vs. 20.6%; P < 0.001). Independent predictors of HPR included Black race, hemoglobin levels, and presence of CYP2C19 loss‐of‐function allele. In the PCI cohort, Black participants had a higher risk of MACE (HR 1.47; 95% CI 1.02–2.11; P = 0.037), primarily driven by MI (HR 1.71; 95% CI 1.09–2.67; P = 0.019), with no significant difference in clinically significant bleeding (HR 1.08; 95% CI 0.65–1.80; P = 0.768). Black participants on clopidogrel exhibit higher platelet reactivity, increased rates of HPR, and an elevated risk of MACE within 1 year after PCI, without significant differences in bleeding compared to non‐Black participants.

  • Open Access

    CYP2C19 Phenotype, P2Y 12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy

    by Rajiv C. Patel, Cameron D. Thomas, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Amber L. Beitelshees, Julio D. Duarte, Luis Ortega‐Paz, Natasha Kulick, Marshall Winget, et al.

    Background: Use of CYP2C19 genotyping to guide antiplatelet therapy is associated with improved clinical outcomes in patients naïve to P2Y 12 inhibitors undergoing percutaneous coronary intervention. The relationship between CYP2C19 genotype and clinical outcomes in patients on maintenance clopidogrel at the time of percutaneous coronary intervention is unknown. Methods: This was a retrospective, multicenter cohort study. Patients were characterized as intermediate or poor metabolizers versus normal or rapid or ultrarapid metabolizers on the basis of CYP2C19 genotype. Major adverse cardiovascular events included cardiovascular death, myocardial infarction, ischemic stroke, or stent thrombosis. Results: The study population (N=4246) had a median age of 63.0 (interquartile range, 55.0–71.0) years, was 66.8% men, and 21.3% Black individuals. During 12‐month follow‐up, major adverse cardiovascular event rates were higher (7.4% versus 4.8%; P 12 inhibitor naïve cohort (n=3367). In weighted Cox regression models of the maintenance clopidogrel cohort, major adverse cardiovascular event risk did not significantly differ in the clopidogrel‐treated intermediate/poor metabolizer group versus clopidogrel‐treated normal/rapid/UM metabolizer group (hazard ratio [HR], 0.88 [95% CI, 0.41–1.86]) versus the prasugrel‐ or ticagrelor‐treated group (HR, 0.73 [95% CI, 0.28–1.87]), although the confidence intervals were wide. In contrast, weighted major adverse cardiovascular events risk in the P2Y 12 inhibitor naïve cohort was higher in the clopidogrel‐treated intermediate or poor metabolizers group compared with clopidogrel‐treated normal/rapid/ultrarapid metabolizer group or prasugrel‐ or ticagrelor‐treated group. Conclusions: Patients on maintenance clopidogrel at the time of percutaneous coronary intervention represent a higher‐risk patient population than patients who are naïve to P2Y 12 inhibitors and genotype‐guided P2Y 12 inhibitor selection at the time of percutaneous coronary intervention may not provide clinical benefit.


  • Open Access

    Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies

    by Larisa H. Cavallari, Craig R. Lee, Francesco Franchi, Ellen C. Keeley, Joseph S. Rossi, Cameron D. Thomas, Yan Gong, Caitrin W. McDonough, Petr Starostik, Maryam J. Al Saeed, et al.

    Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is indicated after percutaneous coronary intervention (PCI) to reduce the risk of atherothrombotic events. Approximately 30% of the US population has a CYP2C19 no‐function allele that reduces the effectiveness of clopidogrel, but not prasugrel or ticagrelor, after PCI. We have shown improved outcomes with the integration of CYP2C19 genotyping into clinical care to guide the selection of prasugrel or ticagrelor in CYP2C19 no‐function allele carriers. However, the influence of patient‐specific demographic, clinical, and other genetic factors on outcomes with genotype‐guided DAPT has not been defined. In addition, the impact of genotype‐guided de‐escalation from prasugrel or ticagrelor to clopidogrel in patients without a CYP2C19 no‐function allele has not been investigated in a diverse, real‐world clinical setting. The Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry is a multicenter US registry of patients who underwent PCI and clinical CYP2C19 testing. The registry is enrolling a diverse population, assessing atherothrombotic and bleeding events over 12 months, collecting DNA samples, and conducting platelet function testing in a subset of patients. The registry aims to define the influence of African ancestry and other patient‐specific factors on clinical outcomes with CYP2C19‐guided DAPT, evaluate the safety and effectiveness of CYP2C19‐guided DAPT de‐escalation following PCI in a real‐world setting, and identify additional genetic influences of clopidogrel response after PCI, with the ultimate goal of establishing optimal strategies for individualized antiplatelet therapy that improves outcomes in a diverse, real‐world population.


  • Evaluating the Effect of Estimating Renal Function With the CKD‐EPI 2021 Equation on the ABCD‐GENE Score for Clopidogrel Response Prediction

    by Maryam Jamal AlSaeed, Cameron D. Thomas, Francesco Franchi, Ellen C. Keeley, Julio D. Duarte, Yan Gong, Joseph S. Rossi, Amber L. Beitelshees, George A. Stouffer, Craig R. Lee, et al.

    The ABCD‐GENE score was developed to predict poor response to clopidogrel and includes Age, Body mass index, Chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2), Diabetes, and CYP2C19 GENE variants; a score ≥ 10 is predictive of reduced clopidogrel effectiveness after percutaneous coronary intervention (PCI). Estimation of GFR without a race variable via the CKD‐EPI Scr 2021 equation is now recommended. We examined the impact of using the CKD‐EPI Scr 2021 vs. 2009 equation on the ABCD‐GENE score for post‐PCI patients. A total of 4335 adult patients (n = 925 Black) who underwent PCI and CYP2C19 genotyping were included, with GFR estimated for each patient via the CKD‐EPI Scr 2021 and CKD‐EPI 2009 equations. The ABCD‐GENE score, calculated based on each GFR estimation, was compared. With the CKD‐EPI Scr 2021 vs. 2009 equation, median (IQR) eGFR was lower (74 [55–94] vs. 81 [60–103] mL/min/1.73 m2, P < 0.001), and CKD prevalence was higher (31% vs. 25%, P < 0.001) among Black patients, whereas eGFR was higher (85 [65–99] vs. 80 [61–94] mL/min/1.73m2, P < 0.001), and CKD prevalence was lower (20% vs. 24%, P < 0.001) in non‐Black patients. This led to 12 (1%) Black patients being reclassified from low to high risk of poor clopidogrel response and 30 (1%) non‐Black patients being recategorized from high to low risk (P < 0.001 for both comparisons). Removal of the race variable from GFR estimation significantly impacted the prediction of clopidogrel effectiveness via the ABCD‐GENE score.


  • Open Access

    CYP2C19 Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention

    by Kayla R. Tunehag, Cameron D. Thomas, Francesco Franchi, Joseph S. Rossi, Ellen C. Keeley, R. David Anderson, Amber L. Beitelshees, Julio D. Duarte, Yan Gong, Richard A. Kerensky, et al.

    Background: Cytochrome P450 2C19 (CYP2C19) intermediate and poor metabolizer patients exhibit diminished clopidogrel clinical effectiveness after percutaneous coronary intervention (PCI). However, outcome studies to date have lacked racial diversity. Thus, the impact of CYP2C19 genotype on cardiovascular outcomes in patients treated with clopidogrel who identify as Black or African American remains unclear. Methods and Results: Adults among 5 institutions who self‐identified as Black or African American, underwent PCI and clinical CYP2C19 genotyping, and were treated with clopidogrel were included. Data were abstracted from health records. Major atherothrombotic (composite of death, myocardial infarction, ischemic stroke, stent thrombosis, or revascularization for unstable angina) and bleeding event rates within 1 year after PCI were compared across CYP2C19 metabolizer groups using multivariable Cox regression adjusted for potential confounders and baseline variables meeting a threshold of P P =0.008). Bleeding event rates were low overall (23 of 567 [4.1%]) and did not differ among the metabolizer groups. Conclusions: Black patients with CYP2C19 intermediate and poor metabolizer phenotypes who are treated with clopidogrel exhibit increased risk of adverse cardiovascular outcomes after PCI in a real‐world clinical setting. Bleeding outcomes should be interpreted cautiously. Prospective studies are needed to determine whether genotype‐guided use of prasugrel or ticagrelor in intermediate and poor metabolizers improves outcomes in Black patients undergoing PCI.